/FSTX

FSTX Stock - F-star Therapeutics, Inc.

Q: What is the analyst price target for FSTX?

Analyst price target information is not currently available for FSTX.

Q: What is FSTX's market cap?

Market capitalization information is not currently available for FSTX.

Healthcare|Biotechnology|NASDAQ

$7.12+0.00%

+$0.00 (+0.00%) • Mar 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $7.83

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for FSTX

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.35

52W High$7.12

52W Low$2.07

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$21.17M	$11.26M	$28.32M	N/A	N/A
Gross Profit	$21.17M	$11.26M	$28.32M	N/A	N/A
Gross Margin	100.0%	100.0%	100.0%	N/A	N/A
Operating Income	$-30,714,000	$-22,385,000	$-22,497,000	$-28,470,000	$-21,253,000
Net Income	$-31,283,000	$-25,619,000	$-23,013,000	$-22,854,000	$-27,679,000
Net Margin	-147.8%	-227.6%	-81.3%	N/A	N/A
EPS	$-1.88	$-2.82	$-2.54	$-1.60	$-2.50

Company Overview

F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

Average Target

↓ 1.7% Downside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
July 15th 2022	H.C. Wainwright	Downgrade	Neutral	$7← $35

Earnings History & Surprises

FSTX

Beat Rate

67%

Last 18 quarters

Avg Surprise

+42.9%

EPS vs Estimate

Beats / Misses

12/6

Last 12 quarters

Latest EPS

$0.47

Q1 2023

EPS Surprise History

Q2 21

+6.9%

$-1.08vs$-1.16

Q3 21

-24.3%

$-0.92vs$-0.74

Q4 21

+10.3%

$-0.52vs$-0.58

Q1 22

+536.4%

$0.48vs$-0.11

Q2 22

+14.9%

$-0.57vs$-0.67

Q3 22

-51.7%

$-0.88vs$-0.58

Q4 22

-6.3%

$-0.84vs$-0.79

Q1 23

+220.5%

$0.47vs$-0.39

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2023	May 8, 2023	$-0.39	—	—	—
Q1 2023	Mar 22, 2023	$-0.39	$0.47	+220.5%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.79	$-0.84	-6.3%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.58	$-0.88	-51.7%	✗ MISS
Q2 2022	May 10, 2022	$-0.67	$-0.57	+14.9%	✓ BEAT
Q1 2022	Mar 14, 2022	$-0.11	$0.48	+536.4%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.58	$-0.52	+10.3%	✓ BEAT
Q3 2021	Aug 12, 2021	$-0.74	$-0.92	-24.3%	✗ MISS
Q2 2021	May 17, 2021	$-1.16	$-1.08	+6.9%	✓ BEAT
Q4 2020	Dec 31, 2020	—	$-0.50	—	—
Q4 2020	Nov 3, 2020	$-1.00	$-1.24	-24.0%	✗ MISS
Q3 2020	Aug 10, 2020	$-1.44	$-1.52	-5.6%	✗ MISS
Q2 2020	May 7, 2020	$-0.80	$-1.96	-145.0%	✗ MISS
Q1 2020	Feb 14, 2020	$-2.68	$-1.80	+32.8%	✓ BEAT
Q4 2019	Nov 7, 2019	$-2.43	$-1.68	+30.9%	✓ BEAT
Q3 2019	Jul 31, 2019	$-2.22	$-1.12	+49.5%	✓ BEAT
Q2 2019	Apr 29, 2019	$-2.09	$-1.28	+38.8%	✓ BEAT
Q1 2019	Mar 11, 2019	$-2.26	$-1.36	+39.8%	✓ BEAT
Q4 2018	Oct 25, 2018	$-0.61	$-0.59	+3.3%	✓ BEAT
Q3 2018	Aug 1, 2018	$-0.53	$-0.29	+45.3%	✓ BEAT

Frequently Asked Questions about FSTX

What is FSTX's current stock price?

F-star Therapeutics, Inc. (FSTX) is currently trading at $7.12 per share. The stock has moved +0.00% today.

What is the analyst price target for FSTX?

No analyst price targets are currently available for this stock.

What sector is F-star Therapeutics, Inc. in?

F-star Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is FSTX's market cap?

F-star Therapeutics, Inc. has a market capitalization of $0.16 billion, making it a small-cap company.

Does FSTX pay dividends?

No, F-star Therapeutics, Inc. does not currently pay a dividend to shareholders.